Fullerenol nanoparticles as a new delivery system for doxorubicin
2016
Аутори
Jović, Danica S.Seke, Mariana N.
Đorđević, Aleksandar N.
Mrdanović, Jasminka Z.
Aleksić, Lidija D.
Bogdanović, Gordana M.
Pavić, Aleksandar
Plavec, Janez
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Doxorubicin is a very potent chemotherapeutic drug, however its side effects limit its clinical use. The aim of this research was to investigate the properties of a fullerenol/doxorubicin nanocomposite, its potentially cytotoxic and genotoxic effects on malignant cell lines, as well as its toxicity towards zebra fish embryos. Chromatographic, NMR and mass spectral analysis of the nanocomposite imply that interactions between doxorubicin and fullerenol are non-covalent bonds. The stability of the nanocomposite was confirmed by the use of atomic force microscopy, dynamic light scattering and transmission electron microscopy. The nanocomposite, compared to the free doxorubicin at equivalent concentrations, significantly decreased the viability of MCF-7 and MDA-MB-231 cells. The flow cytometry results indicated that doxorubicin-loaded fullerenol could remarkably increase the uptake of doxorubicin suggesting that fullerenol might be a promising intracellular targeting carrier for the effici...ent delivery of antitumor drugs into tumor cells. The nanocomposite also affected cell cycle distribution. A genotoxicity test showed that the nanocomposite at all examined concentrations on MCF-7 and at lower concentrations on MDA-MB-231 cells caused DNA damage. Consequently, cell proliferation was notably reduced when compared with controls. Results of the zebrafish embryotoxicity assay showed a decreased overall toxicity, particularly cardiotoxicity and increased safety of the nanocomposite in comparison to doxorubicin alone, as manifested by a higher survival of embryos and less pericardial edema.
Извор:
RSC Advances, 2016, 6, 45, 38563-38578Издавач:
- Royal Soc Chemistry, Cambridge
Финансирање / пројекти:
- Функционални, функционализовани и усавршени нано материјали (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-45005)
- Изучавање микробиолошког диверзитета и карактеризација корисних срединских микроорганизама (RS-MESTD-Basic Research (BR or ON)-173048)
DOI: 10.1039/c6ra03879d
ISSN: 2046-2069
WoS: 000374972800010
Scopus: 2-s2.0-84969245787
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Jović, Danica S. AU - Seke, Mariana N. AU - Đorđević, Aleksandar N. AU - Mrdanović, Jasminka Z. AU - Aleksić, Lidija D. AU - Bogdanović, Gordana M. AU - Pavić, Aleksandar AU - Plavec, Janez PY - 2016 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/981 AB - Doxorubicin is a very potent chemotherapeutic drug, however its side effects limit its clinical use. The aim of this research was to investigate the properties of a fullerenol/doxorubicin nanocomposite, its potentially cytotoxic and genotoxic effects on malignant cell lines, as well as its toxicity towards zebra fish embryos. Chromatographic, NMR and mass spectral analysis of the nanocomposite imply that interactions between doxorubicin and fullerenol are non-covalent bonds. The stability of the nanocomposite was confirmed by the use of atomic force microscopy, dynamic light scattering and transmission electron microscopy. The nanocomposite, compared to the free doxorubicin at equivalent concentrations, significantly decreased the viability of MCF-7 and MDA-MB-231 cells. The flow cytometry results indicated that doxorubicin-loaded fullerenol could remarkably increase the uptake of doxorubicin suggesting that fullerenol might be a promising intracellular targeting carrier for the efficient delivery of antitumor drugs into tumor cells. The nanocomposite also affected cell cycle distribution. A genotoxicity test showed that the nanocomposite at all examined concentrations on MCF-7 and at lower concentrations on MDA-MB-231 cells caused DNA damage. Consequently, cell proliferation was notably reduced when compared with controls. Results of the zebrafish embryotoxicity assay showed a decreased overall toxicity, particularly cardiotoxicity and increased safety of the nanocomposite in comparison to doxorubicin alone, as manifested by a higher survival of embryos and less pericardial edema. PB - Royal Soc Chemistry, Cambridge T2 - RSC Advances T1 - Fullerenol nanoparticles as a new delivery system for doxorubicin EP - 38578 IS - 45 SP - 38563 VL - 6 DO - 10.1039/c6ra03879d ER -
@article{ author = "Jović, Danica S. and Seke, Mariana N. and Đorđević, Aleksandar N. and Mrdanović, Jasminka Z. and Aleksić, Lidija D. and Bogdanović, Gordana M. and Pavić, Aleksandar and Plavec, Janez", year = "2016", abstract = "Doxorubicin is a very potent chemotherapeutic drug, however its side effects limit its clinical use. The aim of this research was to investigate the properties of a fullerenol/doxorubicin nanocomposite, its potentially cytotoxic and genotoxic effects on malignant cell lines, as well as its toxicity towards zebra fish embryos. Chromatographic, NMR and mass spectral analysis of the nanocomposite imply that interactions between doxorubicin and fullerenol are non-covalent bonds. The stability of the nanocomposite was confirmed by the use of atomic force microscopy, dynamic light scattering and transmission electron microscopy. The nanocomposite, compared to the free doxorubicin at equivalent concentrations, significantly decreased the viability of MCF-7 and MDA-MB-231 cells. The flow cytometry results indicated that doxorubicin-loaded fullerenol could remarkably increase the uptake of doxorubicin suggesting that fullerenol might be a promising intracellular targeting carrier for the efficient delivery of antitumor drugs into tumor cells. The nanocomposite also affected cell cycle distribution. A genotoxicity test showed that the nanocomposite at all examined concentrations on MCF-7 and at lower concentrations on MDA-MB-231 cells caused DNA damage. Consequently, cell proliferation was notably reduced when compared with controls. Results of the zebrafish embryotoxicity assay showed a decreased overall toxicity, particularly cardiotoxicity and increased safety of the nanocomposite in comparison to doxorubicin alone, as manifested by a higher survival of embryos and less pericardial edema.", publisher = "Royal Soc Chemistry, Cambridge", journal = "RSC Advances", title = "Fullerenol nanoparticles as a new delivery system for doxorubicin", pages = "38578-38563", number = "45", volume = "6", doi = "10.1039/c6ra03879d" }
Jović, D. S., Seke, M. N., Đorđević, A. N., Mrdanović, J. Z., Aleksić, L. D., Bogdanović, G. M., Pavić, A.,& Plavec, J.. (2016). Fullerenol nanoparticles as a new delivery system for doxorubicin. in RSC Advances Royal Soc Chemistry, Cambridge., 6(45), 38563-38578. https://doi.org/10.1039/c6ra03879d
Jović DS, Seke MN, Đorđević AN, Mrdanović JZ, Aleksić LD, Bogdanović GM, Pavić A, Plavec J. Fullerenol nanoparticles as a new delivery system for doxorubicin. in RSC Advances. 2016;6(45):38563-38578. doi:10.1039/c6ra03879d .
Jović, Danica S., Seke, Mariana N., Đorđević, Aleksandar N., Mrdanović, Jasminka Z., Aleksić, Lidija D., Bogdanović, Gordana M., Pavić, Aleksandar, Plavec, Janez, "Fullerenol nanoparticles as a new delivery system for doxorubicin" in RSC Advances, 6, no. 45 (2016):38563-38578, https://doi.org/10.1039/c6ra03879d . .